0.3752

3.07% -0.013

After Hours: .38 0.0048 +1.28%

Generation Bio Co (GBIO)

Overview News Price History Option Chain Financials Why GBIO Down? Discussions Forecast

Generation Bio Co stock is traded at $0.3752, with a volume of 256.90K. It is down -3.07% in the last 24 hours and down -13.11% over the past month. Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Previous Close:

$0.3882

Open:

$0.3879

24h Volume:

256.90K

Relative Volume:

0.55

Market Cap:

$25.15M

Revenue:

Net Income/Loss:

$-126.61M

P/E Ratio:

-0.1914

EPS:

-1.96

Net Cash Flow:

$-60.14M

1W Performance:

+1.68%

1M Performance:

-13.11%

6M Performance:

-75.24%

1Y Performance:

-88.42%

1-Day Range:

$0.3657

$0.3898

1-Week Range:

$0.3657

$0.4051

52-Week Range:

$0.316

$3.65

Generation Bio Co Stock (GBIO) Company Profile

Name

Generation Bio Co

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

857-529-5908

Address

301 BINNEY STREET, CAMBRIDGE

Employee

115

Twitter

@generationbio

Next Earnings Date

2025-03-12

Latest SEC Filings

GBIO's Discussions on Twitter

Compare GBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GBIO Generation Bio Co	0.3752	25.47M	0	-126.61M	-60.14M	-1.96
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	441.85	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.52	64.44B	14.09B	4.50B	2.96B	39.28

Generation Bio Co Stock (GBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-19-23	Downgrade	TD Cowen	Outperform → Market Perform
Nov-08-22	Initiated	Canaccord Genuity	Buy
Dec-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
Feb-24-21	Initiated	William Blair	Outperform
Feb-18-21	Initiated	Needham	Buy
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	JP Morgan	Overweight
Jul-07-20	Initiated	Jefferies	Buy
Jul-07-20	Initiated	Wedbush	Outperform

View All

Generation Bio Co Stock (GBIO) Latest News

May 28, 2025

Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025

Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference | GBIO Stock News - GuruFocus

May 28, 2025

Generation Bio Reveals Latest T Cell Therapy Progress: CEO Set for Major Jefferies Healthcare Conference Spotlight - Stock Titan

May 28, 2025

May 27, 2025

D. E. Shaw & Co. Inc. Has $366,000 Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World

May 27, 2025

Generation Bio’s SWOT analysis: t-cell targeting tech reshapes stock outlook - Investing.com Nigeria

May 27, 2025

May 22, 2025

Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace

May 22, 2025

May 17, 2025

Dimensional Fund Advisors LP Has $420,000 Stock Holdings in Generation Bio Co. (NASDAQ:GBIO) - Defense World

May 17, 2025

May 12, 2025

Wedbush Issues Negative Forecast for Generation Bio Earnings - Defense World

May 12, 2025

May 10, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Generation Bio (NASDAQ:GBIO) - Defense World

May 10, 2025

May 09, 2025